AC Immune SA SMA 50
Was ist das SMA 50 von AC Immune SA?
SMA 50 von AC Immune SA ist $3 -14.06%
Was ist die Definition von SMA 50?
SMA 50 ist ein durchschnittlicher Aktienkurs der letzten 50 Tage, berechnet als ungewichteter Mittelwert der 50 letzten Schlusskurse.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu AC Immune SA
Was macht AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Unternehmen mit sma 50 ähnlich AC Immune SA
- THL Credit hat SMA 50 von $3 +3.46%
- Impex Ferro Tech hat SMA 50 von ₨3 +8.27%
- Weiqiao Textile hat SMA 50 von HKD$3 +0.07%
- Dare Bioscience Inc hat SMA 50 von $3 -7.03%
- Red Lion Hotels hat SMA 50 von $3 +0.00%
- APN Convenience Retail REIT hat SMA 50 von AUD$3 +0.00%
- AC Immune SA hat SMA 50 von $3 -14.06%
- Haitong Securities Co hat SMA 50 von HKD$3 +4.61%
- Avalon GloboCare hat SMA 50 von $3 -564.58%
- Vistagen Therapeutics hat SMA 50 von $3 -10.95%
- Gran Colombia Gold hat SMA 50 von CAD$3 -12.38%
- Avalon GloboCare hat SMA 50 von $3 -564.58%
- Alps Industries hat SMA 50 von ₨3 +4.66%